Skip to main
SOLV

Solventum Corporation (SOLV) Stock Forecast & Price Target

Solventum Corporation (SOLV) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 18%
Buy 45%
Hold 27%
Sell 0%
Strong Sell 9%

Bulls say

Solventum is a promising healthcare company with strong financials and potential for growth due to its innovative solutions and focus on material science and digital capabilities. The recent spinoff from 3M has allowed Solventum to streamline operations and focus on growth in key segments. Furthermore, they have a steady cadence of M&A and potential for divestiture in non-core product areas, providing additional flexibility for growth. With a solid Q1 performance and a strong outlook for 2026, we believe SOLV will continue to progress towards their 2028 financial targets and maintain our Buy rating and raised price target of $93.

Bears say

Solventum is facing a challenging healthcare market with slowing organic growth and increased competition. Furthermore, the company's dependence on the United States for the majority of its revenue exposes it to potential regulatory risks and changes in healthcare spending. Additionally, delays in the spin-off or execution of portfolio optimization could weigh on the company's growth prospects. The company's valuation also remains questionable, as it trades at a lower P/E multiple compared to peers with higher growth rates and could face downward pressure in an already competitive market.

Solventum Corporation (SOLV) has been analyzed by 11 analysts, with a consensus rating of Buy. 18% of analysts recommend a Strong Buy, 45% recommend Buy, 27% suggest Holding, 0% advise Selling, and 9% predict a Strong Sell.

This aggregate rating is based on analysts' research of Solventum Corporation and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Solventum Corporation (SOLV) Forecast

Analysts have given Solventum Corporation (SOLV) a Buy based on their latest research and market trends.

According to 11 analysts, Solventum Corporation (SOLV) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $86.27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $86.27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Solventum Corporation (SOLV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.